Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.88%29.51B | 11.23%8.2B | 1.99%7.45B | 3.62%7.22B | -5.64%6.65B | -1.71%28.68B | -15.23%7.37B | 13.22%7.3B | -7.43%6.97B | 8.17%7.05B |
Cost of revenue | 1.26%21.91B | 7.05%5.99B | 0.93%5.47B | 7.04%5.52B | -9.80%4.93B | -1.88%21.64B | -16.98%5.6B | 17.07%5.42B | -9.27%5.16B | 9.32%5.46B |
Gross profit | 7.85%7.6B | 24.42%2.21B | 5.03%1.97B | -6.17%1.7B | 8.63%1.72B | -1.17%7.04B | -9.20%1.77B | 3.40%1.88B | -1.75%1.81B | 4.41%1.59B |
Operating expense | 5.13%6.22B | 6.45%1.69B | 5.02%1.54B | 6.85%1.53B | 2.04%1.45B | 8.67%5.92B | 10.82%1.59B | 2.29%1.47B | 8.45%1.43B | 13.75%1.42B |
Staff costs | 3.02%3.37B | ---- | ---- | ---- | ---- | 8.54%3.27B | ---- | ---- | ---- | ---- |
Selling and administrative expenses | 3.72%702.09M | ---- | ---- | ---- | ---- | 9.04%676.88M | ---- | ---- | ---- | ---- |
-Selling and marketing expense | 10.43%39.76M | ---- | ---- | ---- | ---- | -18.20%36.01M | ---- | ---- | ---- | ---- |
-General and administrative expense | 3.35%662.33M | ---- | ---- | ---- | ---- | 11.12%640.87M | ---- | ---- | ---- | ---- |
Research and development costs | 3.59%452.88M | ---- | ---- | ---- | ---- | 24.77%437.18M | ---- | ---- | ---- | ---- |
Depreciation and amortization | 3.50%186.31M | ---- | ---- | ---- | ---- | 0.93%180.01M | ---- | ---- | ---- | ---- |
-Depreciation | 3.50%186.31M | ---- | ---- | ---- | ---- | 0.93%180.01M | ---- | ---- | ---- | ---- |
Rent and land expenses | 3.99%308.24M | ---- | ---- | ---- | ---- | 7.85%296.42M | ---- | ---- | ---- | ---- |
Other operating expenses | 13.81%1.2B | ---- | ---- | ---- | ---- | 4.81%1.06B | ---- | ---- | ---- | ---- |
Operating profit | 22.08%1.38B | 182.91%510.84M | 5.09%431.78M | -56.33%162.61M | 65.22%273.65M | -32.94%1.13B | -64.98%180.56M | 7.56%410.88M | -27.87%372.37M | -38.76%165.62M |
Net non-operating interest income (expenses) | 35.35%-94.2M | 106.39%2.45M | 47.44%-23.33M | 20.90%-27.08M | -61.33%-46.25M | -31.40%-145.7M | -26.27%-38.41M | -51.94%-44.38M | -37.45%-34.24M | -8.81%-28.66M |
Non-operating interest income | 104.27%87.46M | 109.45%41.47M | 176.83%18.86M | 134.01%20.64M | -12.06%6.49M | -4.03%42.82M | 36.20%19.8M | -22.51%6.81M | -23.69%8.82M | -24.08%7.39M |
Non-operating interest expense | -3.63%181.66M | -32.97%39.02M | -17.61%42.18M | 10.84%47.72M | 46.30%52.74M | 21.23%188.51M | 29.48%58.21M | 34.72%51.2M | 18.07%43.06M | -0.06%36.05M |
Net investment income | -14.01%218.97M | 749.88%30.66M | 32.53%49.48M | 29.19%28.72M | -42.49%110.11M | 33.71%254.63M | -96.89%3.61M | 6.38%37.34M | 12.36%22.23M | 877.61%191.46M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -574.81%-190.16M | -223.65M | 0 | 40.05M | 0 | 21.9M | ||||
Income from associates and other participating interests | -15.82%18.07M | 117.46%7.22M | -19.12%3.35M | -53.11%2.62M | -42.02%4.88M | 11.25%21.46M | 21.78%3.32M | -5.81%4.14M | 62.95%5.59M | -3.76%8.41M |
Special income (charges) | -100.62%-9.31M | 79.76%-28.61M | -99.97%115K | -99.70%1.35M | -97.68%17.83M | 178.29%1.5B | -126.94%-141.35M | 716,616.95%422.75M | 25,683.65%454.31M | 5,431.20%767.84M |
Less:Other special charges | 100.63%9.31M | -82.06%28.61M | 99.97%-115K | 99.70%-1.35M | 97.68%-17.83M | -178.57%-1.49B | 130.81%159.49M | -716,616.95%-422.75M | -25,683.65%-454.31M | -5,431.20%-767.84M |
Less:Write off | --0 | ---- | ---- | ---- | ---- | -157.06%-18.14M | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | 69.69%128.43M | 192.88%51.86M | 28.00%39.43M | 321.76%16.63M | -40.82%20.52M | -4.67%75.68M | 195.86%17.71M | 17.96%30.8M | -190.81%-7.5M | -45.39%34.67M |
Income before tax | -49.61%1.45B | 1,279.38%350.76M | -43.31%500.83M | -73.72%218.33M | -66.58%380.74M | 19.82%2.88B | -97.71%25.43M | 111.18%883.42M | 58.41%830.92M | 225.69%1.14B |
Income tax | -20.60%482.49M | 388.66%140.71M | -32.49%144.63M | -78.97%33.15M | -42.36%163.99M | -6.84%607.65M | -118.25%-48.75M | 40.89%214.25M | 9.70%157.63M | 218.13%284.52M |
Net income | -57.38%968.17M | 183.19%210.06M | -46.77%356.2M | -72.50%185.18M | -74.64%216.74M | 29.76%2.27B | -91.20%74.18M | 151.32%669.18M | 76.78%673.29M | 228.29%854.82M |
Net income continuous operations | -57.38%968.17M | 183.19%210.06M | -46.77%356.2M | -72.50%185.18M | -74.64%216.74M | 29.76%2.27B | -91.20%74.18M | 151.32%669.17M | 76.78%673.29M | 228.29%854.82M |
Noncontrolling interests | -79.77%182.55M | 338.64%81.32M | -76.78%56.34M | -91.17%24.74M | -95.13%20.15M | 112.01%902.51M | -111.42%-34.08M | 464.13%242.67M | 297.21%280.17M | 2,911.02%413.74M |
Net income attributable to the company | -42.61%785.62M | 18.92%128.74M | -29.69%299.86M | -59.19%160.43M | -55.43%196.6M | 3.33%1.37B | -80.12%108.25M | 91.05%426.5M | 26.68%393.12M | 78.83%441.08M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -42.61%785.62M | 18.92%128.74M | -29.69%299.86M | -59.19%160.43M | -55.43%196.6M | 3.33%1.37B | -80.12%108.25M | 91.05%426.5M | 26.68%393.12M | 78.83%441.08M |
Gross dividend payment | ||||||||||
Basic earnings per share | -40.79%199.68 | 21.59%33.4 | -27.26%76.59 | -57.81%40.73 | -54.62%48.96 | 4.42%337.22 | -79.31%27.47 | 93.50%105.3 | 27.64%96.55 | 79.47%107.9 |
Diluted earnings per share | -40.79%199.68 | 23.26%33.1305 | -27.26%76.59 | -57.80%40.73 | -54.62%48.96 | 4.42%337.22 | -79.75%26.8781 | 93.52%105.3 | 27.61%96.5254 | 79.47%107.9 |
Dividend per share | 31.25%105 | 31.25%105 | 0 | 0 | 0 | 0.00%80 | 0.00%80 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |